All In Biotech

Drug Trial Radar · NCT05963074

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients With Previously Untreated Chronic Lymphocytic Leukemia

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

333

Actual

Start

May 30, 2024

Primary completion

Dec 15, 2027

Study completion Mar 19, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Pharmacyclics LLC.
First posted
Jul 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Small Lymphocytic Lymphoma

Interventions

  • IbrutinibDrug

    Ibrutinib capsules will be administered orally.

  • VenetoclaxDrug

    Venetoclax tablets will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall Response Rate (ORR)Time frame: Up to 5 years

Locations

74 sites in 8 countries. Site status is shown where the registry gives one.

  • The Oncology Institute Clinical Research

    Cerritos, California

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • SLO Oncology and Hematology Health Center

    San Luis Obispo, California

  • Providence Medical Foundation

    Santa Rosa, California

  • PIH Health Hospital

    Whittier, California

  • Grand Valley Oncology

    Grand Junction, Colorado

  • Mount Sinai Medical Center Campus

    Miami Beach, Florida

  • The Oncology Institute

    North Miami Beach, Florida

  • Mid Florida Hematology Oncology

    Orange, Florida

  • Boise VA Medical Center

    Boise, Idaho

  • Hope and Healing Cancer Services

    Hinsdale, Illinois

  • Springfield Clinic

    Springfield, Illinois

  • Iowa City VA Health Care System

    Iowa City, Iowa

  • Minnesota Oncology Hematology P A

    Minneapolis, Minnesota

  • Research Medical Center

    Kansas City, Missouri

  • Hunterdon Hematology Oncology

    Flemington, New Jersey

  • Summit Medical Group

    Florham Park, New Jersey

  • Hematology Oncology Associates of Rockland

    Nyack, New York

  • Southeastern Medical Oncology Center

    Goldsboro, North Carolina

  • Oncology Hematology Care

    Cincinnati, Ohio

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon

  • OHSU Knight Cancer Institute

    Portland, Oregon

  • Renovatio Clinical

    El Paso, Texas

  • Texas Oncology-Fort Worth Cancer Center

    Fort Worth, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Renovatio Clinical 1

    The Woodlands, Texas

  • Texas Oncology-Gulf Coast

    The Woodlands, Texas

  • Community Cancer Trials of Utah

    Ogden, Utah

  • Virginia Cancer Specialists

    Manassas, Virginia

  • Virginia Oncology Associates

    Virginia Beach, Virginia

  • VA Puget Sound Healthcare System

    Seattle, Washington

  • Northwest Cancer Specialists PC

    Vancouver, Washington

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Niagara Health System

    St. Catharines, Ontario, Canada

  • Fakultni nemocnice Brno

    Brno-Bohunice, Czechia

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • Fakultni Nemocnice Ostrava

    Ostrava - Poruba, Czechia

  • Fakultni nemocnice Kralovske Vinohrady

    Prague, Czechia

  • Ustav Hematologie A Krevni Transfuze

    Prague, Czechia

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.